OBJECTIVE: To examine the impact of Toll-like receptor 5 (TLR-5) on endothelial cell function in rheumatoid arthritis (RA) and vascularization in collagen-induced arthritis (CIA). METHODS: Endothelial cell migration and tube formation assays were used to demonstrate the direct role of TLR-5 ligation in angiogenesis. Mice with CIA were treated with the TLR-5 agonist flagellin to document the effect of TLR-5 ligation in RA pathology. Vascularization in CIA was determined by immunohistochemical analysis and determination of cytokine levels in ankle joints. Spleen Th17 cells and joint interleukin-17 (IL-17) were quantified by fluorescence-activated cell sorting analysis and enzyme-linked immunosorbent assay. The development of Th17 cells induced by TLR-5 ligation was validated in RA peripheral blood mononuclear cells. RESULTS: Ligation of TLR-5 to endogenous ligands expressed in RA synovial fluid contributed to endothelial cell infiltration and tube formation. Furthermore, treatment with flagellin after the onset of CIA exacerbated joint inflammation; in contrast, inflammation in control mice remained at a plateau phase. We showed that TLR-5-enhanced disease severity was attributable to Th17 cell differentiation and joint vascularization in CIA. Examination of the underlying mechanism using RA peripheral blood mononuclear cells documented that ligation of TLR-5 in myeloid cells and production of Th17-promoting cytokines were necessary for Th17 cell polarization. Additionally, we demonstrated that blockade of the IL-17 cascade markedly reduced endothelial cell migration activated by flagellin-conditioned medium, suggesting that TLR-5 ligation can mediate RA angiogenesis either directly by attracting endothelial cells or indirectly by fostering Th17 cell development. CONCLUSION: Our data demonstrate a novel role for TLR-5 in RA angiogenesis; thus, TLR-5 may be a promising new target for RA treatment.
OBJECTIVE: To examine the impact of Toll-like receptor 5 (TLR-5) on endothelial cell function in rheumatoid arthritis (RA) and vascularization in collagen-induced arthritis (CIA). METHODS: Endothelial cell migration and tube formation assays were used to demonstrate the direct role of TLR-5 ligation in angiogenesis. Mice with CIA were treated with the TLR-5 agonist flagellin to document the effect of TLR-5 ligation in RA pathology. Vascularization in CIA was determined by immunohistochemical analysis and determination of cytokine levels in ankle joints. Spleen Th17 cells and joint interleukin-17 (IL-17) were quantified by fluorescence-activated cell sorting analysis and enzyme-linked immunosorbent assay. The development of Th17 cells induced by TLR-5 ligation was validated in RA peripheral blood mononuclear cells. RESULTS: Ligation of TLR-5 to endogenous ligands expressed in RA synovial fluid contributed to endothelial cell infiltration and tube formation. Furthermore, treatment with flagellin after the onset of CIA exacerbated joint inflammation; in contrast, inflammation in control mice remained at a plateau phase. We showed that TLR-5-enhanced disease severity was attributable to Th17 cell differentiation and joint vascularization in CIA. Examination of the underlying mechanism using RA peripheral blood mononuclear cells documented that ligation of TLR-5 in myeloid cells and production of Th17-promoting cytokines were necessary for Th17 cell polarization. Additionally, we demonstrated that blockade of the IL-17 cascade markedly reduced endothelial cell migration activated by flagellin-conditioned medium, suggesting that TLR-5 ligation can mediate RA angiogenesis either directly by attracting endothelial cells or indirectly by fostering Th17 cell development. CONCLUSION: Our data demonstrate a novel role for TLR-5 in RA angiogenesis; thus, TLR-5 may be a promising new target for RA treatment.
Authors: Nathan D Chamberlain; Olga M Vila; Michael V Volin; Suncica Volkov; Richard M Pope; William Swedler; Arthur M Mandelin; Shiva Shahrara Journal: J Immunol Date: 2012-06-01 Impact factor: 5.422
Authors: Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Nicholas E Talarico; Arthur M Mandelin; Shiva Shahrara Journal: Arthritis Rheum Date: 2012-08
Authors: Grace Pinhal-Enfield; Madhuri Ramanathan; Gyorgy Hasko; Stefanie N Vogel; Andrew L Salzman; Geert-Jan Boons; S Joseph Leibovich Journal: Am J Pathol Date: 2003-08 Impact factor: 4.307
Authors: Reinhart Seibl; Thomas Birchler; Susanne Loeliger; Johann Peter Hossle; Renate E Gay; Traudl Saurenmann; Beat A Michel; Reinhard A Seger; Steffen Gay; Roger P Lauener Journal: Am J Pathol Date: 2003-04 Impact factor: 4.307
Authors: Hatem A Elshabrawy; Abdul E Essani; Zoltán Szekanecz; David A Fox; Shiva Shahrara Journal: Autoimmun Rev Date: 2016-12-15 Impact factor: 9.754
Authors: Sadiq Umar; Karol Palasiewicz; Michael V Volin; Bianca Romay; Rani Rahat; Chandana Tetali; Shiva Arami; Monica Guma; Christian Ascoli; Nadera Sweiss; Ryan K Zomorrodi; Luke A J O'Neill; Shiva Shahrara Journal: Cell Mol Life Sci Date: 2021-10-27 Impact factor: 9.261
Authors: Seung-Jae Kim; Zhenlong Chen; Nathan D Chamberlain; Abdul B Essani; Michael V Volin; M Asif Amin; Suncica Volkov; Ellen M Gravallese; Shiva Arami; William Swedler; Nancy E Lane; Anjali Mehta; Nadera Sweiss; Shiva Shahrara Journal: J Immunol Date: 2014-09-08 Impact factor: 5.422
Authors: Ying Wang; Yingmei Wei; Xiu Cheng; Xiaojin Sun; Linyan Ma; Yining Song; Jing Zhou; Fang Wei; Hao Liu Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2018-07-30
Authors: Zhenlong Chen; Seung-Jae Kim; Abdul B Essani; Michael V Volin; Olga M Vila; William Swedler; Shiva Arami; Suncica Volkov; Latriese V Sardin; Nadera Sweiss; Shiva Shahrara Journal: Ann Rheum Dis Date: 2014-05-15 Impact factor: 19.103
Authors: Sadiq Umar; Karol Palasiewicz; Katrien Van Raemdonck; Michael V Volin; Bianca Romay; M Asif Amin; Ryan K Zomorrodi; Shiva Arami; Mark Gonzalez; Vikram Rao; Brian Zanotti; David A Fox; Nadera Sweiss; Shiva Shahrara Journal: Cell Mol Immunol Date: 2020-05-15 Impact factor: 22.096